Ruthanne Williams Roussel: While VVUS in strongest cash position of peers to negotiate partnership, OREX & ARNA also attractive, poss getting overlooked today
Ruthanne Williams Roussel: Working on explanation of "intent to treat" data v. "completer" aka "per-protocol" data (what OREX released Sat). FDA looks at ITT